Published in Catheter Cardiovasc Interv on April 25, 2012
Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol (2016) 0.86
Circulatory support with Impella CP device during high-risk percutaneous coronary interventions: initial experience in Poland. Postepy Kardiol Interwencyjnej (2016) 0.81
Early feasibility testing and engineering development of the transapical approach for the HeartWare MVAD ventricular assist system. ASAIO J (2014) 0.80
Use of impella ventricular assist device in patients with severe coronary artery disease presenting with cardiac arrest. Int J Angiol (2012) 0.77
Percutaneous Mechanical Ventricular Support in Acute Cardiac Care: A UK Quaternary Centre Experience Using 2.5L, 3.8L and 5.0L Impella Catheters. Cardiol Ther (2014) 0.77
Percutaneous Hemodynamic Support (Impella) in Patients with Advanced Heart Failure and/or Cardiogenic Shock Not Eligible to PROTECT II Trial. Int J Angiol (2013) 0.75
Percutaneous Ventricular Assist Devices: A Health Technology Assessment. Ont Health Technol Assess Ser (2017) 0.75
Impending savior: Impella 2.5 circulatory support system in high-risk PCI. Catheter Cardiovasc Interv (2012) 0.75
The Duration of Impella 2.5 Circulatory Support and Length of Hospital Stay of Patients Undergoing High-risk Percutaneous Coronary Interventions. Cardiol Res (2012) 0.75
Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ (2004) 3.99
Evaluation of advanced access in the national primary care collaborative. Br J Gen Pract (2004) 3.48
Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool. BMJ (2007) 3.28
Prevalence of Takotsubo cardiomyopathy in the United States. Am Heart J (2012) 3.15
Risk of acute kidney injury after percutaneous coronary interventions using radial versus femoral vascular access: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Interv (2014) 2.67
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv (2010) 2.52
Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation (2007) 2.43
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation (2002) 2.39
Factors associated with poorer prognosis for patients undergoing primary percutaneous coronary intervention during off-hours: biology or systems failure? JACC Cardiovasc Interv (2008) 2.22
Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics (2013) 2.12
A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation (2012) 2.08
Clinical correlates and prognostic significance of electrocardiographic abnormalities in apical ballooning syndrome (Takotsubo/stress-induced cardiomyopathy). Am Heart J (2009) 2.01
Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther (2012) 1.95
Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol (2005) 1.77
Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv (2012) 1.73
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2011) 1.70
Stenting and angioplasty with protection in patients at high-risk for endarterectomy: SAPPHIRE Worldwide Registry first 2,001 patients. Catheter Cardiovasc Interv (2009) 1.67
Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca⁺⁺ trial. Catheter Cardiovasc Interv (2014) 1.65
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2011) 1.59
Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT ΙΙ study. Catheter Cardiovasc Interv (2013) 1.50
Costs of transradial percutaneous coronary intervention. JACC Cardiovasc Interv (2013) 1.47
Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol (2006) 1.46
The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol (2013) 1.46
Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Qual Outcomes (2013) 1.44
The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv (2013) 1.40
Nine-month results of the REFORM study: a prospective, single-arm, multicenter clinical study of the safety and effectiveness of the Formula™ balloon-expandable stent for treatment of renal artery stenosis. Catheter Cardiovasc Interv (2013) 1.40
Computer therapy compared with usual care for people with long-standing aphasia poststroke: a pilot randomized controlled trial. Stroke (2012) 1.40
Feasibility of a pressure wire and single arterial puncture for assessing aortic valve area in patients with aortic stenosis. J Invasive Cardiol (2006) 1.40
Intravascular thermographic assessment in human coronary atherosclerotic plaques by a novel flow-occluding sensing catheter: a safety and feasibility study. J Invasive Cardiol (2005) 1.39
A prospective, randomized, pivotal trial of a novel extravascular collagen-based closure device compared to manual compression in diagnostic and interventional patients. J Invasive Cardiol (2015) 1.39
Angiographic and clinical characteristics of type 1 versus type 2 perioperative myocardial infarction. Catheter Cardiovasc Interv (2013) 1.39
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv (2009) 1.39
Distal protection during primary angioplasty: a feasibility and safety study utilizing a novel filter technology. J Invasive Cardiol (2006) 1.38
Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. JACC Cardiovasc Interv (2009) 1.38
Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail (2005) 1.38
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2011) 1.27
Effectiveness of paramedic practitioners in attending 999 calls from elderly people in the community: cluster randomised controlled trial. BMJ (2007) 1.24
Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the randomized assessment of treatment using panel Assay of cardiac markers (RATPAC) trial. Acad Emerg Med (2011) 1.21
A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol (2003) 1.20
Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother (2009) 1.19
Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes. J Am Coll Cardiol (2004) 1.18
Psychological treatment for insomnia in the management of long-term hypnotic drug use: a pragmatic randomised controlled trial. Br J Gen Pract (2003) 1.13
The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health (2005) 1.11
Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation (2010) 1.08
The role of patient preferences in cost-effectiveness analysis: a conflict of values? Pharmacoeconomics (2009) 1.08
Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol (2003) 1.05
Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J (2007) 1.05
Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J (2005) 1.04
Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv (2009) 1.02
Adjunctive thrombectomy and distal protection in primary percutaneous coronary intervention: impact on microvascular perfusion and outcomes. Circulation (2009) 1.01
Predicting longer-term outcomes following psychological treatment for hypnotic-dependent chronic insomnia. J Psychosom Res (2003) 0.98
Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol (2005) 0.98
Parametric modelling of cost data: some simulation evidence. Health Econ (2005) 0.97
Percutaneous endocardial and epicardial ablation of hypotensive ventricular tachycardia with percutaneous left ventricular assist in the electrophysiology laboratory. J Cardiovasc Electrophysiol (2007) 0.96
Time-dependent ARMA modeling of genomic sequences. BMC Bioinformatics (2008) 0.96
Looking inside the black box of community rehabilitation and intermediate care teams in the United Kingdom: an audit of service and staffing. Qual Prim Care (2009) 0.95
Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol (2013) 0.92
Transcatheter device closure of interatrial septal defects in patients with hypoxia. J Interv Cardiol (2005) 0.91
A Bayesian meta-analysis comparing AngioJet thrombectomy to percutaneous coronary intervention alone in acute myocardial infarction. J Interv Cardiol (2008) 0.91
Carbon nanostructure-based field-effect transistors for label-free chemical/biological sensors. Sensors (Basel) (2010) 0.91
Neutrophil gelatinase-associated lipocalin: a novel marker of contrast nephropathy risk. Am J Nephrol (2012) 0.89
Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol (2003) 0.89
Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J (2007) 0.88
Deleterious effects of sleep-disordered breathing on the heart and vascular system. Respiration (2005) 0.88
Direct monitoring of coronary artery motion with cardiac fat navigator echoes. Magn Reson Med (2003) 0.88
Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial. Diabetes Care (2014) 0.88
Revascularization strategies of coronary multiple vessel disease in the Drug Eluting Stent Era: one year follow-up results of the ERACI III Trial. EuroIntervention (2006) 0.87
The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol (2003) 0.86
Extracorporeal membrane oxygenation for advanced refractory shock in acute and chronic cardiomyopathy. Ann Thorac Surg (2011) 0.86
Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. Pharmacoeconomics (2006) 0.86
Temporal changes in the outcomes of patients with diabetes mellitus undergoing percutaneous coronary intervention in the National Heart, Lung, and Blood Institute dynamic registry. Am Heart J (2011) 0.86
Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. Am J Cardiol (2012) 0.86
Pupil staging and EEG measurement of sleepiness. Int J Psychophysiol (2004) 0.86
Frequency of returning to work one and six months following percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol (2004) 0.86
Platelet abnormalities in diabetes mellitus. Coron Artery Dis (2003) 0.86
Protection of Distal Embolization in High-Risk Patients with Acute ST-Segment Elevation Myocardial Infarction (PREMIAR). Am J Cardiol (2006) 0.86
The science behind percutaneous hemodynamic support: a review and comparison of support strategies. Catheter Cardiovasc Interv (2012) 0.85
Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol (2003) 0.84
Left ventricular systolic and diastolic function in patients with apical ballooning syndrome compared with patients with acute anterior ST-segment elevation myocardial infarction: a functional paradox. Mayo Clin Proc (2009) 0.84
Breath-hold 3D steady-state free precession coronary MRA compared with conventional X-ray coronary angiography. J Magn Reson Imaging (2006) 0.84
Association of health insurance status with presentation and outcomes of coronary artery disease among nonelderly adults undergoing percutaneous coronary intervention. Am Heart J (2011) 0.84
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol (2005) 0.84